You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Author Index Volume 2 (2016)

The issue number is given in front of the pagination

Abe, T., see Osawa, T. (2) 251–261

Aben, K.K., see Grotenhuis, A.J. (1) 77–89

Abida, W., M.I. Milowsky, I. Ostrovnaya, S.R. Gerst, J.E. Rosenberg,M.H. Voss, A.B. Apolo, A.M. Regazzi, A.S. McCoy, M.E. Boyd and D.F. Bajorin, Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma (1) 111–117

Abrams, J.S., see Lerner, S.P. (2) 165–202

Agarwal, P., see Kamat, A.M. (2) 203–213

Ahmed, O., see Boström, P.J. (1) 101–109

Al-Ahmadie, H., see Lerner, S.P. (2) 165–202

Allen, E.V., see Lerner, S.P. (2) 165–202

Amiri, A.T., see Lerner, S.P. (2) 165–202

Apolo, A.B., see Abida, W. (1) 111–117

Apolo, A.B., see Lerner, S.P. (2) 165–202

Badr, H., see Mohamed, N.E. (2) 139–149

Bagrodia, A., see Passoni, N.M. (1) 91–99

Bajorin, D.F., see Abida, W. (1) 111–117

Bajorin, D.F., see Lerner, S.P. (2) 165–202

Bamias, A., see Leiter, A. (3) 341–349

Bellmunt, J., see Lerner, S.P. (2) 165–202

Bellmunt, J., see Rose, T.L. (4) 405–413

Berry, D., see Mohamed, N.E. (2) 139–149

Bhat, A., M. Mokou, J. Zoidakis, V. Jankowski, A. Vlahou and H. Mischak, BcCluster: A Bladder Cancer Database at the Molecular Level (1) 65–76

Bidnur, S., R. Savdie and P.C. Black, Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer (1) 15–25

Bivalacqua, T., see Kamat, A.M. (2) 203–213

Bivalacqua, T.J., see Kaye, D.R. (2) 225–234

Black, P.C., see Bidnur, S. (1) 15–25

Boorjian, S.A., see Gershman, B., (1) 1–14

Boormans, J.L. and E.C. Zwarthoff, Limited Funds for Bladder Cancer Research and What Can We Do About It (1) 49–51

Boormans, J.L., see van Kessel, K.E.M. (3) 351–360

Borza, T., see Russell, C.M. (4) 381–394

Boström, P.J., J. Thoms, J. Sykes, O. Ahmed, A. Evans, B.W.G. van Rhijn, T. Mirtti, O. Stakhovskyi, M. Laato, D. Margel, M. Pintilie, C. Kuk, M. Milosevic, A.R. Zlotta and R.G. Bristow, Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy (1) 101–109

Boström, P.J., T. Mirtti, B. van Rhijn, N.E. Fleshner, A. Finelli, M. Laato, M.A. Jewett, M.J. Moore, S. Sridhar, M. Nurmi, I.F. Tannock and A.R. Zlotta, Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy (2) 263–272

Boyd, M.E., see Abida, W. (1) 111–117

Brandt, A., see Hoffmann, M.J. (4) 449–463

Bristow, R.G., see Boström, P.J. (1) 101–109

Bryan, R.T., see D’Costa, J.J. (3) 301–317

Bulbul, M., see Shahait, M. (4) 467–468

Burkhard, F.C., see Kiss, B. (1) 53–59

Callahan, M., see Lerner, S.P. (2) 165–202

Canner, J.K., see Kaye, D.R. (2) 225–234

Cappelletti, V., see Fina, E. (4) 395–403

Casey, M.F., J. Wisnivesky, V.H. Le, U. Sarpel, K.D. Stensland, W.K. Oh and M.D. Galsky, The Relationship between Centralization of Care and Geographic Barriers to Cystectomy for Bladder Cancer (3) 319–327

Cha, E.K., see Lerner, S.P. (2) 165–202

Chan, K.S., see Lerner, S.P. (1) 37–47

Chandrasekar, T., N. Pugashetti, B. Durbin-Johnson, M.A. Dall’Era, C.P. Evans, R.W. deVere White and S.A. Yap, Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact? (4) 441–448

Chisolm, S., see Kamat, A.M. (2) 203–213

Choudhury, A., see Mirza, A. (2) 151–163

Chowdhury, S., see Rose, T.L. (4) 405–413

Colecchia, M., see Fina, E. (4) 395–403

Cookson, M., see Kamat, A.M. (2) 273–278

Créhange, G., see Rose, T.L. (4) 405–413

D’Costa, J.J., J.C. Goldsmith, J.S. Wilson, R.T. Bryan and D.G. Ward, A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer (3) 301–317

Daidone, M.G., see Fina, E. (4) 395–403

Dall’Era, M.A., see Chandrasekar, T. (4) 441–448

Daneshmand, S., see Kamat, A.M. (2) 203–213

Danna, B.J., M.J. Metcalfe, E.L. Wood and J.B. Shah, Assessing Symptom Burden in Bladder Cancer: An Overview of Bladder Cancer Specific Health-Related Quality of Life Instruments (3) 329–340

de Haan, L.M., see van Kessel, K.E.M. (3) 351–360

de Wit, R., see van Kessel, K.E.M. (3) 351–360

Deal, A.M., see Rose, T.L. (4) 405–413

DeCastro, G.J., see Sui, W. (4) 415–423

deVere White, R.W., see Chandrasekar, T. (4) 441–448

Dinney, C.P., see Lerner, S.P. (2) 165–202

Doroshow, J.H., see Kamat, A.M. (2) 203–213

Doucette, J., see Leiter, A. (3) 341–349

Douglass, L. and M. Schoenberg, The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer (3) 285–292

Downs, T., see Mohamed, N.E. (2) 139–149

Drake, C., see Lerner, S.P. (2) 165–202

Dudek, A.M., see Grotenhuis, A.J. (1) 77–89

Dunn, R.L., see Luckenbaugh, A.N. (2) 235–240

Durbin-Johnson, B., see Chandrasekar, T. (4) 441–448

Ecke, T., see Leiter, A. (3) 341–349

Efstathiou, J.A., see Kamat, A.M. (2) 203–213

Efstathiou, J.A., see Lerner, S.P. (2) 165–202

Englesbe, M.J., see Luckenbaugh, A.N. (2) 235–240

Erlmeier, F., A.K. Seitz, G. Hatzichristodoulou, L. Stecher, M. Retz, J.E. Gschwend, W. Weichert, H.R. Kübler and T. Horn, The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma (4) 425–432

Evans, A., see Boström, P.J. (1) 101–109

Evans, C.P., see Chandrasekar, T. (4) 441–448

Fahmy, O., see Gakis, G. (3) 293–300

Fahmy, O., see Godoy, G. (2) 127–137

Fina, E., A. Necchi, P. Giannatempo, M. Colecchia, D. Raggi, M.G. Daidone and V. Cappelletti, Clinical Significance of Early Changes in Circulating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma (4) 395–403

Finelli, A., see Boström, P.J. (2) 263–272

Fleshner, N.E., see Boström, P.J. (2) 263–272

Francis, F., see Passoni, N.M. (1) 91–99

Fransen van de Putte, E.E., see van Kessel, K.E.M. (3) 351–360

Friedman, J.F., see Luckenbaugh, A.N. (2) 235–240

Fulkerson, C.M., see Knapp, D.W. (2) 241–250

Gakis, G. and O. Fahmy, Systematic Review and Meta-Analysis on the Impact of Hexaminolevulinate- Versus White-Light Guided Transurethral Bladder Tumor Resection on Progression in Non-Muscle Invasive Bladder Cancer (3) 293–300

Gakis, G., see Godoy, G. (2) 127–137

Galsky, M., see Kamat, A.M. (2) 203–213

Galsky, M.D., see Casey, M.F. (3) 319–327

Galsky, M.D., see Leiter, A. (3) 341–349

Galsky, M.D., see Rose, T.L. (4) 405–413

Gershman, B., S.A. Boorjian and R.E. Hautmann, Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know? (1) 1–14

Gerst, S.R., see Abida, W. (1) 111–117

Giannatempo, P., see Fina, E. (4) 395–403

Gilbert, F., see Mohamed, N.E. (2) 139–149

Gilbert, S.M., see Luckenbaugh, A.N. (2) 235–240

Gills, J., see Zuk, K. (4) 433–439

Given, B., see Mohamed, N.E. (2) 139–149

Godoy, G., O. Fahmy, C.L. Smith and G. Gakis, Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression (2) 127–137

Goldsmith, J.C., see D’Costa, J.J. (3) 301–317

Groshen, S., see Lerner, S.P. (2) 165–202

Grossman, H.B., see Kamat, A.M. (2) 273–278

Grotenhuis, A.J., A.M. Dudek, G.W. Verhaegh, K.K. Aben, J.A. Witjes, L.A. Kiemeney and S.H. Vermeulen, Independent Replication of Published Germline Polymorphisms Associated with Urinary Bladder Cancer Prognosis and Treatment Response (1) 77–89

Gschwend, J.E., see Erlmeier, F. (4) 425–432

Hafez, K.S., see Osawa, T. (2) 251–261

Hahn, N., see Leiter, A. (3) 341–349

Hahn, N.M., see Lerner, S.P. (2) 165–202

Hansel, D., see Lerner, S.P. (2) 165–202

Harshman, L.C., see Rose, T.L. (4) 405–413

Hatzichristodoulou, G., see Erlmeier, F. (4) 425–432

Hautmann, R.E., see Gershman, B., (1) 1–14

Hoadley, K.A., see Lerner, S.P. (1) 37–47

Hoffmann, M.J., E. Koutsogiannouli, M.A. Skowron, M. Pinkerneil, G. Niegisch, A. Brandt, S. Stepanow, H. Rieder and W.A. Schulz, The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors (4) 449–463

Höglund, M., see Lerner, S.P. (1) 37–47

Hollenbeck, B.K., see Luckenbaugh, A.N. (2) 235–240

Hollenbeck, B.K., see Osawa, T. (2) 251–261

Hollingsworth, J.M., see Luckenbaugh, A.N. (2) 235–240

Holzbeierlein, J.M., see Zuk, K. (4) 433–439

Honkisz, S.I., see Knapp, D.W. (2) 241–250

Horn, T., see Erlmeier, F. (4) 425–432

Iyer, G., see Kamat, A.M. (2) 203–213

Izawa, J., see Power, N.E. (1) 27–36

James, M.B., see Sui, W. (4) 415–423

Jankowski, V., see Bhat, A. (1) 65–76

Jarow, J., see Lerner, S.P. (2) 165–202

Jensen, D., see Zuk, K. (4) 433–439

Jewett, M.A., see Boström, P.J. (2) 263–272

Kamat, A., see Lerner, S.P. (2) 165–202

Kamat, A.M., M. Cookson, J.A. Witjes, A. Stenzl and H.B. Grossman, The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer – A New Analysis (2) 273–278

Kamat, A.M., P. Agarwal, T. Bivalacqua, S. Chisolm, S. Daneshmand, J.H. Doroshow, J.A. Efstathiou, M. Galsky, G. Iyer, W. Kassouf, J. Shah, J. Taylor, S.B. Williams, D.Z. Quale and J.E. Rosenberg, Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank (2) 203–213

Kapur, P., see Passoni, N.M. (1) 91–99

Kassouf, W., see Kamat, A.M. (2) 203–213

Kates, M., see Kaye, D.R. (2) 225–234

Kaye, D.R., J.K. Canner, M. Kates, M.P. Schoenberg and T.J. Bivalacqua, Do African American Patients Treated with Radical Cystectomy for Bladder Cancer have Worse Overall Survival? Accounting for Pathologic Staging and Patient Demographics Beyond Race Makes a Difference (2) 225–234

Kiemeney, L.A., see Grotenhuis, A.J. (1) 77–89

Kim, W., see Lerner, S.P. (2) 165–202

Kim, W.Y., see Lerner, S.P. (1) 37–47

Kiss, B. and B. Roth, Reply from Authors to the Editorial Comment (1) 63–64

Kiss, B., M. Paerli, D. Schöndorf, F.C. Burkhard, G.N. Thalmann and B. Roth, Pelvic Lymph Node Dissection may be Limited on the Contralateral Side in Strictly Unilateral Bladder Cancer without Compromising Oncological Radicality (1) 53–59

Knapp, D.W., A. Ruple-Czerniak, J.A. Ramos-Vara, J.F. Naughton, C.M. Fulkerson and S.I. Honkisz, A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma (2) 241–250

Knauer, C., see Mohamed, N.E. (2) 139–149

Knowles, M., see Lerner, S.P. (2) 165–202

Koutsogiannouli, E., see Hoffmann, M.J. (4) 449–463

Krege, S., see Leiter, A. (3) 341–349

Kübler, H.R., see Erlmeier, F. (4) 425–432

Kuk, C., see Boström, P.J. (1) 101–109

Kwiatkowski, D., see Lerner, S.P. (2) 165–202

Laato, M., see Boström, P.J. (1) 101–109

Laato, M., see Boström, P.J. (2) 263–272

Ladoire, S., see Rose, T.L. (4) 405–413

Le, V.H., see Casey, M.F. (3) 319–327

Lebastchi, A.H., see Russell, C.M. (4) 381–394

Lee, C.T., see Luckenbaugh, A.N. (2) 235–240

Lee, C.T., see Mohamed, N.E. (2) 139–149

Lee, C.T., see Osawa, T. (2) 251–261

Lee, E.K., see Zuk, K. (4) 433–439

Leiter, A., J. Doucette, S. Krege, C.-C. Lin, N. Hahn, T. Ecke, G. Sonpavde, A. Bamias, W.K. Oh and M.D. Galsky, Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma (3) 341–349

Lerner, S.P., D.F. Bajorin, C.P. Dinney, J.A. Efstathiou, S. Groshen, N.M. Hahn, D. Hansel, D. Kwiatkowski, M. O’Donnell, J. Rosenberg, R. Svatek, J.S. Abrams, H. Al-Ahmadie, A.B. Apolo, J. Bellmunt, M. Callahan, E.K. Cha, C. Drake, J. Jarow, A. Kamat, W. Kim, M. Knowles, B. Mann, L. Marchionni, D. McConkey, L. McShane, N. Ramirez, A. Sharabi, A.H. Sharpe, D. Solit, C.M. Tangen, A.T. Amiri, E.V. Allen, P.J. West, J.A. Witjes and D.Z. Quale, Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer (2) 165–202

Lerner, S.P., D.J. McConkey, K.A. Hoadley, K.S. Chan, W.Y. Kim, F. Radvanyi, M. Höglund and F.X. Real, Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting (1) 37–47

Lin, C.-C., see Leiter, A. (3) 341–349

Liontos, M., see Rose, T.L. (4) 405–413

Lopez–Corona, E., see Zuk, K. (4) 433–439

Lotan, Y., see Passoni, N.M. (1) 91–99

Luckenbaugh, A.N., B.K. Hollenbeck, J.S. Montgomery, C.T. Lee, S.M. Gilbert, R.L. Dunn, J.F. Friedman, M.J. Englesbe, S.C. Wang and J.M. Hollingsworth, Using Analytic Morphomics to Understand Short-Term Convalescence after Radical Cystectomy (2) 235–240

Mann, B., see Lerner, S.P. (2) 165–202

Marchionni, L., see Lerner, S.P. (2) 165–202

Margel, D., see Boström, P.J. (1) 101–109

Matulay, J.T., see Sui, W. (4) 415–423

McConkey, D., see Lerner, S.P. (2) 165–202

McConkey, D.J., see Lerner, S.P. (1) 37–47

McCoy, A.S., see Abida, W. (1) 111–117

McShane, L., see Lerner, S.P. (2) 165–202

Mehrazin, R., see Mohamed, N.E. (2) 139–149

Messing, E.M., Checkpoint Inhibitors for Advanced Bladder Cancer (4) 473–474

Metcalfe, M.J., see Danna, B.J. (3) 329–340

Milosevic, M., see Boström, P.J. (1) 101–109

Milowsky, M.I., see Abida, W. (1) 111–117

Mirtti, T., see Boström, P.J. (1) 101–109

Mirtti, T., see Boström, P.J. (2) 263–272

Mirza, A. and A. Choudhury, Bladder Preservation for Muscle Invasive Bladder Cancer (2) 151–163

Mischak, H., see Bhat, A. (1) 65–76

Mohamed, N.E., F. Gilbert, C.T. Lee, J. Sfakianos, C. Knauer, R. Mehrazin, H. Badr, D. Wittman, T. Downs, D. Berry, B. Given, P. Wiklund and G. Steineck, Pursuing Quality in the Application of Bladder Cancer Quality of Life Research (2) 139–149

Mokou, M., see Bhat, A. (1) 65–76

Montgomery, J.S., see Luckenbaugh, A.N. (2) 235–240

Montgomery, J.S., see Osawa, T. (2) 251–261

Moore, M.J., see Boström, P.J. (2) 263–272

Morgan, T.M., see Osawa, T. (2) 251–261

Morgan, T.M., see Russell, C.M. (4) 381–394

Mott, S.L., see Steinberg, R.L. (2) 215–224

Murai, S., see Osawa, T. (2) 251–261

Nandagopal, L. and G. Sonpavde, Circulating Biomarkers in Bladder Cancer (4) 369–379

Naughton, J.F., see Knapp, D.W. (2) 241–250

Necchi, A., see Fina, E. (4) 395–403

Niegisch, G., see Hoffmann, M.J. (4) 449–463

Niegisch, G., see Rose, T.L. (4) 405–413

Nurmi, M., see Boström, P.J. (2) 263–272

O’Donnell, M., see Lerner, S.P. (2) 165–202

O’Donnell, M.A., see Steinberg, R.L. (2) 215–224

Oh, W.K., see Casey, M.F. (3) 319–327

Oh, W.K., see Leiter, A. (3) 341–349

Onyeji, I.C., see Sui, W. (4) 415–423

Osawa, T., C.T. Lee, T. Abe, N. Takada, K.S. Hafez, J.S. Montgomery, A.Z. Weizer, B.K. Hollenbeck, T.A. Skolarus, S. Murai, N. Shinohara and T.M. Morgan, A Multi-Center International Study Assessing the Impact of Differences in Baseline Characteristics and Perioperative Care Following Radical Cystectomy (2) 251–261

Ostrovnaya, I., see Abida, W. (1) 111–117

Paerli, M., see Kiss, B. (1) 53–59

Passoni, N.M., S.F. Shariat, A. Bagrodia, F. Francis, V. Rachakonda, E. Xylinas, P. Kapur, A.I. Sagalowsky and Y. Lotan, Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study (1) 91–99

Pinkerneil, M., see Hoffmann, M.J. (4) 449–463

Pintilie, M., see Boström, P.J. (1) 101–109

Power, N.E. and J. Izawa, Comparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE) (1) 27–36

Pugashetti, N., see Chandrasekar, T. (4) 441–448

Quale, D.Z., see Kamat, A.M. (2) 203–213

Quale, D.Z., see Lerner, S.P. (2) 165–202

Rachakonda, V., see Passoni, N.M. (1) 91–99

Radvanyi, F., see Lerner, S.P. (1) 37–47

Raggi, D., see Fina, E. (4) 395–403

Ramirez, N., see Lerner, S.P. (2) 165–202

Ramos-Vara, J.A., see Knapp, D.W. (2) 241–250

Real, F.X., see Lerner, S.P. (1) 37–47

Regazzi, A.M., see Abida, W. (1) 111–117

Retz, M., see Erlmeier, F. (4) 425–432

Rieder, H., see Hoffmann, M.J. (4) 449–463

Rose, T.L., A.M. Deal, S. Ladoire, G. Créhange, M.D. Galsky, J.E. Rosenberg, J. Bellmunt, A. Wimalasingham, Y.-N. Wong, L.C. Harshman, S. Chowdhury, G. Niegisch, M. Liontos, Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer (4) 405–413

Rosenberg, J., see Lerner, S.P. (2) 165–202

Rosenberg, J.E., see Abida, W. (1) 111–117

Rosenberg, J.E., see Kamat, A.M. (2) 203–213

Rosenberg, J.E., see Rose, T.L. (4) 405–413

Roth, B., see Kiss, B. (1) 53–59

Roth, B., see Kiss, B. (1) 63–64

RoyChoudhury, A., see Sui, W. (4) 415–423

Ruple-Czerniak, A., see Knapp, D.W. (2) 241–250

Russell, C.M., A.H. Lebastchi, T. Borza, D.E. Spratt and T.M. Morgan, The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer (4) 381–394

Sagalowsky, A.I., see Passoni, N.M. (1) 91–99

Sarpel, U., see Casey, M.F. (3) 319–327

Savdie, R., see Bidnur, S. (1) 15–25

Schoenberg, M., see Douglass, L. (3) 285–292

Schoenberg, M.P., see Kaye, D.R. (2) 225–234

Schöndorf, D., see Kiss, B. (1) 53–59

Schulz, W.A., see Hoffmann, M.J. (4) 449–463

Seitz, A.K., see Erlmeier, F. (4) 425–432

Sfakianos, J., see Mohamed, N.E. (2) 139–149

Shah, J., see Kamat, A.M. (2) 203–213

Shah, J.B., see Danna, B.J. (3) 329–340

Shahait, M. and M. Bulbul, Bladder Cancer Screening in Lebanese Population: There is Nothing more Unequal than the Equal Treatment of Unequal People (4) 467–468

Sharabi, A., see Lerner, S.P. (2) 165–202

Shariat, S.F., see Passoni, N.M. (1) 91–99

Sharpe, A.H., see Lerner, S.P. (2) 165–202

Shinohara, N., see Osawa, T. (2) 251–261

Skolarus, T.A., see Osawa, T. (2) 251–261

Skowron, M.A., see Hoffmann, M.J. (4) 449–463

Smith, C.L., see Godoy, G. (2) 127–137

Solit, D., see Lerner, S.P. (2) 165–202

Soloway, M.S. Challenging Cases in Urothelial Cancer (4) 465–466

Sonpavde, G., see Leiter, A. (3) 341–349

Sonpavde, G., see Nandagopal, L. (4) 369–379

Spratt, D.E., see Russell, C.M. (4) 381–394

Sridhar, S., see Boström, P.J. (2) 263–272

Stakhovskyi, O., see Boström, P.J. (1) 101–109

Stecher, L., see Erlmeier, F. (4) 425–432

Steinberg, R.L., L.J. Thomas, S.L. Mott and M.A. O’Donnell, Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease (2) 215–224

Steineck, G., see Mohamed, N.E. (2) 139–149

Stensland, K.D., see Casey, M.F. (3) 319–327

Stenzl, A., see Kamat, A.M. (2) 273–278

Stepanow, S., see Hoffmann, M.J. (4) 449–463

Sui, W., J.T. Matulay, M.B. James, I.C. Onyeji, M.C. Theofanides, A. RoyChoudhury, G.J. DeCastro and S. Wenske, Micropapillary Bladder Cancer: Insights from the National Cancer Database (4) 415–423

Svatek, R., see Lerner, S.P. (2) 165–202

Sykes, J., see Boström, P.J. (1) 101–109

Takada, N., see Osawa, T. (2) 251–261

Tangen, C.M., see Lerner, S.P. (2) 165–202

Tannock, I.F., see Boström, P.J. (2) 263–272

Taylor, J., see Kamat, A.M. (2) 203–213

Thalmann, G.N., see Kiss, B. (1) 53–59

Theofanides, M.C., see Sui, W. (4) 415–423

Thomas, L.J., see Steinberg, R.L. (2) 215–224

Thoms, J., see Boström, P.J. (1) 101–109

van der Heijden, M.S., see van Kessel, K.E.M. (3) 351–360

van Kessel, K.E.M., L.M. de Haan, E.E. Fransen van de Putte, B.W.G. van Rhijn, R. de Wit, M.S. van der Heijden, E.C. Zwarthoff and J.L. Boormans, Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder Cancer (3) 351–360

van Rhijn, B., see Boström, P.J. (2) 263–272

van Rhijn, B.W.G., see Boström, P.J. (1) 101–109

van Rhijn, B.W.G., see van Kessel, K.E.M. (3) 351–360

Verhaegh, G.W., see Grotenhuis, A.J. (1) 77–89

Vermeulen, S.H., see Grotenhuis, A.J. (1) 77–89

Vlahou, A., see Bhat, A. (1) 65–76

Voss, M.H., see Abida, W. (1) 111–117

Wang, S.C., see Luckenbaugh, A.N. (2) 235–240

Ward, D.G. see D’Costa, J.J. (3) 301–317

Weichert, W., see Erlmeier, F. (4) 425–432

Weizer, A.Z., see Osawa, T. (2) 251–261

Wenske, S., see Sui, W. (4) 415–423

West, P.J., see Lerner, S.P. (2) 165–202

Wiklund, P., see Mohamed, N.E. (2) 139–149

Williams, S.B., see Kamat, A.M. (2) 203–213

Wilson, J.S., see D’Costa, J.J. (3) 301–317

Wimalasingham, A., see Rose, T.L. (4) 405–413

Wisnivesky, J., see Casey, M.F. (3) 319–327

Witjes, J.A., see Grotenhuis, A.J. (1) 77–89

Witjes, J.A., see Kamat, A.M. (2) 273–278

Witjes, J.A., see Lerner, S.P. (2) 165–202

Wittman, D., see Mohamed, N.E. (2) 139–149

Wong, Y.-N., see Rose, T.L. (4) 405–413

Wood, E.L., see Danna, B.J. (3) 329–340

Wyre, H., see Zuk, K. (4) 433–439

Xylinas, E., see Passoni, N.M. (1) 91–99

Yap, S.A., see Chandrasekar, T. (4) 441–448

Zlotta, A.R., see Boström, P.J. (1) 101–109

Zlotta, A.R., see Boström, P.J. (2) 263–272

Zoidakis, J., see Bhat, A. (1) 65–76

Zuk, K., D. Jensen, J. Gills, H. Wyre, J.M. Holzbeierlein, E. Lopez–Corona and E.K. Lee, The July Effect in Radical Cystectomy: Mortality, Morbidity, and Efficiency (4) 433–439

Zwarthoff, E.C., see Boormans, J.L. (1) 49–51

Zwarthoff, E.C., see van Kessel, K.E.M. (3) 351–360